Aspirin

Aspirin use associated with reduction in cardiovascular events but increase in bleeding risk

1. In this systematic review and meta-analysis, while aspirin use among patients without cardiovascular disease was associated with fewer adverse cardiovascular events, it was not associated with a reduction in all-cause mortality. 2. The use of aspirin in patients without cardiovascular disease was associated with increased risk of major bleeding. Evidence Czytaj więcej…

alteplase

Low-dose intracoronary alteplase unlikely to improve outcomes in STEMI patients treated with primary PCI

1. In this randomized controlled trial, low-dose intracoronary alteplase given early during primary percutaneous coronary intervention (PCI) for acute ST-Elevation Myocardial Infarction (STEMI) did not reduce microvascular obstruction. 2. Health related quality of life was not improved with low-dose intracoronary alteplase. Evidence Rating Level: 1 (Excellent) Study Rundown: Acute coronary Czytaj więcej…

Aspirin

Aspirin alone likely safest antithrombotic therapy after bioprosthetic aortic valve replacement

1. Aspirin combined with warfarin was linked with increased bleeding but not less thromboembolism compared with aspirin alone after bioprosthetic aortic valve replacement. 2. Dual antiplatelet therapy showed a non-significant trend towards increased bleeding but no less thromboembolism compared with aspirin alone after bioprosthetic aortic valve replacement. Evidence Rating Level: Czytaj więcej…

Cardiology

Quick Take: Christmas, National Holidays, Sport Events, and Time Factors as Triggers of Acute Myocardial Infarction: SWEDEHEART Observational Study 1998-2013

Ischemic heart disease, the most common cause of morbidity and mortality worldwide, has many modifiable and non-modifiable risk factors, including several external factors. This retrospective observational study aimed to investigate circadian rhythms, major sports events, and national holidays as potential triggers of myocardial infarction. Investigators reviewed 283,014 cases of myocardial Czytaj więcej…

angioedema

Quick Take: Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial

Hereditary angioedema with C1 inhibitor deficiency is a rare autosomal dominant disorder characterized by C1 inhibitor deficiency (type I) or dysfunction (type II) causing dysregulated plasma kallikrein activity, and in turn, life-threatening recurrent angioedema attacks. The aim of this phase 3, randomized, double-blind, placebo-controlled trial was to assess the efficacy Czytaj więcej…